A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy and Safety of Modzatinib (ATI-2138) in Adult Participants With Biopsy-Proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies (ALPHA)
Aclaris Therapeutics, Inc.
Summary
This study evaluates modzatinib versus placebo in participants with biopsy-proven forms of moderate-to-severe lichen planus (LP).
Eligibility
- Age range
- 18–75 years
- Sex
- All
- Healthy volunteers
- No
Key Inclusion Criteria: * Participants must have biopsy-confirmed OLP, CLP, or LPP eligible for systemic therapy and a history of inadequate response to topical corticosteroids (TCS) of high or ultra-high potency (based on the World Health Organization \[WHO\] definition) for at least 4 weeks in the opinion of the Investigator. Specific criteria for each subtype below: * OLP: OLP IGA of ≥ 3 (moderate or severe) and either Baseline LP-related Pain or Burning Sensation NRS ≥ 3. * CLP: CLP IGA ≥3 (moderate or severe) and Baseline LP-related Itch NRS ≥ 3. * LPP: LPP IGA ≥ 3 (moderate or severe)…
Interventions
- DrugModzatinib
Oral tablets
- DrugPlacebo
Oral tablets
Location
- Aclaris Clinical SiteSavannah, Georgia